Trial Profile
A Phase 1b Trial of AR-42 With Pomalidomide in Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; REC 2282 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 10 Jun 2021 Status changed from suspended to completed.
- 07 Apr 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 07 Apr 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.